Loading
Xenon Pharmaceuticals Inc. Stock: price and insider trades · United States
2 insiders bought €1.5M of shares over the last 90 days, the latest filed 01 Oct 2026.
Cluster: 2 buyers in 30 daysXenon Pharmaceuticals Inc.: what insiders have been doing
Every trade that managers of Xenon Pharmaceuticals Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 67 filings came from 21 insiders.
Both sides are active: 4 purchases worth €2.5M and 12 sales worth €2.2M, from 4 insiders and 8 insiders respectively. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 2 senior executives, 1 finance chief and 1 chief executive. The largest single trade was a purchase of €989k by Mortimer Ian, published on 1 October 2026, equal to 0.032% of the market capitalisation.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 67 filings here. Over the whole record (from 2021), the tally stands at 6 purchases and 22 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 7.5 m USD and net income at -345.9 m USD.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (1 October 2026) now reads 16 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
106
Thresholds
n/a
Buy Volume
€3M
6 ops. · all time
Sell Volume
€6M
22 ops. · all time
Who traded when
BuySaleChristopher John Kenney4 sales
Steven Gannon4 sales
Ian Mortimer1 buy2 sales
Gillian Cannon2 sales
Thomas Patrick Kelly2 buys
Gary Patou1 sale
+1 other insider
Since the insiders bought
- +33.4%Entry US$27.10 · Close at T+365 US$36.15
- +33.1%Entry US$27.45 · Close at T+365 US$36.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Xenon Pharmaceuticals Inc. Strong Buy (bullish), based on 18 analysts. Average price target: US$72.43.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$33.90
Analyst consensus
18 analystsStrong buy
US$46.00Target US$72.43(+114%)US$90.00
Income statement
RevenueUS$7.5M
EBITDA-US$370.5M-4940% margin
Net income-US$345.9M-4612.1% margin
Valuation
PER (forward)-7.2x
P/Book2.6x
Beta0.60
Balance sheet & cash
Market capUS$3.3B
Total debtUS$7.9M
Free Cash Flow-US$279.9M
Debt / Equity1%
Profitability & ownership
ROE-43.6%
ROA-28.0%
% insiders0.2%
% institutions107.3%
Last declaration on 16 October 2026
Declarations106 total
7,500 sharesCommon SharesSEC:0001193125-26-424428:0
15,000 shares@ CA$37.3160.011% mcap100.0% of flowCommon SharesTSXSEDI:4783590
Canonical exit: 29 Dec 2026 (T+90)
Common SharesTSXSEDI:4783584
Common SharesTSXSEDI:4783571
30,000 shares@ CA$37.380.022% mcap100.0% of flowCommon SharesTSXSEDI:4783566
Canonical exit: 29 Dec 2026 (T+90)
15,000 shares@ US$37.3160.016% mcap100.0% of flowCommon SharesSEC:0001193125-26-410001:0
Canonical exit: 29 Dec 2026 (T+90)
30,000 shares@ US$37.380.032% mcap54.7% of flowCommon SharesSEC:0001193125-26-409999:0
Canonical exit: 29 Dec 2026 (T+90)
5,144 shares@ US$8.150.0011% mcap3.9% of flowCommon SharesSEC:0001193125-26-382412:0
700 shares@ CA$60.97660.0009% mcap10.0% of flowCommon SharesTSXSEDI:4771677
6,368 shares@ CA$60.16730.0076% mcap90.0% of flowCommon SharesTSXSEDI:4771676
6,368 shares@ US$60.16730.010% mcap84.7% of flowCommon SharesSEC:0001193125-26-377309:0
700 shares@ US$60.97660.0012% mcap9.4% of flowCommon SharesSEC:0001193125-26-377309:1
7,068 shares@ US$61.930.012% mcap100.0% of flowCommonSEC144:0001950047-26-008816
8,000 shares@ CA$64.0550.010% mcap95.2% of flowCommon SharesTSXSEDI:4764860
2,000 sharesCommon SharesTSXSEDI:4764859
3,500 shares@ CA$7.384.8% of flowCommon SharesTSXSEDI:4764858
3,500 sharesOptionsTSXSEDI:4764857
10,000 shares@ US$64.05530.018% mcap100.0% of flowCommon SharesSEC144:0001193125-26-349336
10,000 shares@ US$64.0550.018% mcap84.7% of flowCommon SharesSEC:0001193125-26-349351:0
1,190 shares@ CA$53.140.0008% mcap100.0% of flowCommon SharesTSXSEDI:4732724
1,322 shares@ CA$53.140.0009% mcap100.0% of flowCommon SharesTSXSEDI:4732723
1,190 shares@ US$53.140.0009% mcap100.0% of flowCommon SharesSEC:0001193125-26-262671:0
1,593 sharesRestricted Share UnitsTSXSEDI:4730770
10,507 sharesOptionsTSXSEDI:4730767
2,645 sharesCommon SharesTSXSEDI:4730761
25 of 106 declarations
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company listed on the Nasdaq in the United States. For investors, XENE is best understood as a specialized clinical-stage biotech with an increasingly commercial profile, rather than a diversified pharmaceutical group. The company’s operating footprint spans Vancouver, British Columbia, and Boston, Massachusetts, reflecting a North American structure that is common among development-stage biotech firms. Xenon’s strategic identity is centered on discovering, developing, and ultimately commercializing therapies for patients with serious neurological disorders, with epilepsy currently the core value driver.
The company’s lead asset is azetukalner, a novel, potent K_V7 potassium channel opener. Xenon is developing it across multiple neurological and neuropsychiatric indications, with the most advanced program in focal onset seizures. In March 2026, Xenon reported positive topline Phase 3 X-TOLE2 data in focal onset seizures and said it was targeting a U.S. FDA New Drug Application filing in the third quarter of 2026. That is a major de-risking milestone and the most important near-term catalyst in the equity story. Xenon also continues to advance additional Phase 3 studies in epilepsy, including programs in primary generalized tonic-clonic seizures, while expanding azetukalner into neuropsychiatry through Phase 3 studies in major depressive disorder and bipolar depression.
Read moreShow less
Beyond azetukalner, Xenon has been building a broader ion-channel platform. Its earlier-stage pipeline includes XEN1701, a Nav1.7 program, and XEN1120, another K_V7 candidate, both being developed for acute pain. This gives the company optionality beyond epilepsy and supports the thesis that Xenon is trying to build a longer-duration neuroscience franchise. From a competitive standpoint, the company sits in a high-barrier segment where differentiated mechanism of action, tolerability, dosing convenience, and robust late-stage data matter as much as headline efficacy. Xenon’s recent disclosures emphasize a favorable safety profile, durable long-term extension data, and sustained clinical momentum, all of which strengthen the case for azetukalner as a potentially differentiated epilepsy therapy.
Recent company updates have also highlighted financial flexibility. Xenon reported a strong pro forma cash position after a capital raise in 2026, extending its runway into the second half of 2027. That matters because the company is nearing a potentially expensive transition from development to launch preparation. Overall, Xenon remains a focused neuroscience biotech with a clearly defined lead asset, meaningful late-stage catalysts, and a growing set of follow-on programs. For U.S. market participants, XENE on Nasdaq is a classic high-upside, high-volatility biotech name whose valuation is likely to remain sensitive to clinical readouts, regulatory timing, and launch execution in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
